167 related articles for article (PubMed ID: 33277542)
1. Positioning of an unprecedented spiro[5.5]undeca ring system into kinase inhibitor space.
Venkanna A; Subedi L; Teli MK; Lama PD; Nangunuri BG; Lee SY; Kim SY; Kim MH
Sci Rep; 2020 Dec; 10(1):21265. PubMed ID: 33277542
[TBL] [Abstract][Full Text] [Related]
2. Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
Dhorma LP; Teli MK; Nangunuri BG; Venkanna A; Ragam R; Maturi A; Mirzaei A; Vo DK; Maeng HJ; Kim MH
Eur J Med Chem; 2022 Jan; 227():113880. PubMed ID: 34656041
[TBL] [Abstract][Full Text] [Related]
3. Chemistry-oriented synthesis (ChOS) and target deconvolution on neuroprotective effect of a novel scaffold, oxaza spiroquinone.
Venkanna A; Cho KH; Dhorma LP; Kumar DN; Hah JM; Park HG; Kim SY; Kim MH
Eur J Med Chem; 2019 Feb; 163():453-480. PubMed ID: 30530196
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
5. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site.
Rippin I; Khazanov N; Shirley Ben Joseph ; Kudinov T; Berent E; Arciniegas Ruiz SM; Marciano D; Levy L; Gruzman A; Senderowitz H; Eldar-Finkelman H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218072
[TBL] [Abstract][Full Text] [Related]
8. Docking and quantitative structure-activity relationship of oxadiazole derivates as inhibitors of GSK3β.
Quesada-Romero L; Caballero J
Mol Divers; 2014 Feb; 18(1):149-59. PubMed ID: 24081608
[TBL] [Abstract][Full Text] [Related]
9. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
Tapia-Rojas C; Schüller A; Lindsay CB; Ureta RC; Mejías-Reyes C; Hancke J; Melo F; Inestrosa NC
Biochem J; 2015 Mar; 466(2):415-30. PubMed ID: 25423492
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
Wang Y; Dou X; Jiang L; Jin H; Zhang L; Zhang L; Liu Z
Eur J Med Chem; 2019 Jun; 171():221-234. PubMed ID: 30925338
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship of the 7-hydroxy benzimidazole analogs as glycogen synthase kinase 3β inhibitor.
Lee SC; Shin D; Cho JM; Ro S; Suh YG
Bioorg Med Chem Lett; 2012 Mar; 22(5):1891-4. PubMed ID: 22325951
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.
Mohammad MK; Al-Masri IM; Taha MO; Al-Ghussein MA; Alkhatib HS; Najjar S; Bustanji Y
Eur J Pharmacol; 2008 Apr; 584(1):185-91. PubMed ID: 18295757
[TBL] [Abstract][Full Text] [Related]
14. 6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.
Uehara F; Shoda A; Aritomo K; Fukunaga K; Watanabe K; Ando R; Shinoda M; Ueno H; Kubodera H; Sunada S; Saito K; Kaji T; Asano S; Eguchi J; Yuki S; Tanaka S; Yoneyama Y; Niwa T
Bioorg Med Chem Lett; 2013 Dec; 23(24):6928-32. PubMed ID: 24094818
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of 7-Chloro-9
Andreev S; Pantsar T; Ansideri F; Kudolo M; Forster M; Schollmeyer D; Laufer SA; Koch P
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242571
[TBL] [Abstract][Full Text] [Related]
16. Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.
Pandey MK; DeGrado TR
Theranostics; 2016; 6(4):571-93. PubMed ID: 26941849
[TBL] [Abstract][Full Text] [Related]
17. Using thermodynamic integration MD simulation to compute relative protein-ligand binding free energy of a GSK3β kinase inhibitor and its analogs.
Lee HC; Hsu WC; Liu AL; Hsu CJ; Sun YC
J Mol Graph Model; 2014 Jun; 51():37-49. PubMed ID: 24858254
[TBL] [Abstract][Full Text] [Related]
18. In silico deconstruction of ATP-competitive inhibitors of glycogen synthase kinase-3β.
Bisignano P; Lambruschini C; Bicego M; Murino V; Favia AD; Cavalli A
J Chem Inf Model; 2012 Dec; 52(12):3233-44. PubMed ID: 23198830
[TBL] [Abstract][Full Text] [Related]
19. Structure-based optimization of oxadiazole-based GSK-3 inhibitors.
Lo Monte F; Kramer T; Gu J; Brodrecht M; Pilakowski J; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
Eur J Med Chem; 2013 Mar; 61():26-40. PubMed ID: 22749643
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin.
Bidon-Chanal A; Fuertes A; Alonso D; Pérez DI; Martínez A; Luque FJ; Medina M
Eur J Med Chem; 2013 Feb; 60():479-89. PubMed ID: 23354070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
